Investigational Drug Details
| Drug ID: | D428 |
| Drug Name: | Fluspirilene |
| Synonyms: | |
| Type: | small molecule |
| DrugBank ID: | DB04842 |
| DrugBank Description: | A long-acting injectable antipsychotic agent used for chronic schizophrenia. |
| PubChem ID: | 3396 |
| CasNo: | 1841-19-6 |
| Repositioning for NAFLD: | Yes |
| SMILES: | FC1=CC=C(C=C1)C(CCCN1CCC2(CC1)N(CNC2=O)C1=CC=CC=C1)C1=CC=C(F)C=C1 |
| Structure: |
|
| InChiKey: | QOYHHIBFXOOADH-UHFFFAOYSA-N |
| Molecular Weight: | 475.5727 |
| DrugBank Targets: | Dopamine D2 receptor; 5-hydroxytryptamine receptor 2A; Voltage-dependent calcium channel gamma-1 subunit |
| DrugBank MoA: | |
| DrugBank Pharmacology: | Fluspirilene is a relatively long-acting injectable depot antipsychotic drug used for schizophrenia. Fluspirilene does not differ greatly from other depot antipsychotics (fluphenazine decanoate, fluphenazine enathate, perphenazine onanthat, pipotiazine undecylenate) with respect to treatment efficacy, response or tolerability. Outcomes suggest that fluspirilene does not differ significantly from oral antipsychotics or in different weekly regimens, although much cannot be inferred because of the shortage of trials. |
| DrugBank Indication: | Used for the treatment of schizophrenia. |
| Targets: | |
| Therapeutic Category: | |
| Clinical Trial Progress: | |
| Latest Progress: |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted |
|---|
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Article ID | PMID | Source | Title |
|---|